News
PerkinElmer to Present at Cowen Health Care Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on
![More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications
Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging
![More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications
Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging
![U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous
![Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020.
Record fourth quarter revenue reflects a strong close to 2020:
-
Revenue of $953
![Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=us)
Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.
Fourth Quarter 2020 Financial Highlights:
-
Revenue grew 23%
![Dexcom Launches Inaugural Venture Capital Fund: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=us)
Dexcom Launches Inaugural Venture Capital Fund
DexCom, Inc. (Nasdaq: DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the launch of Dexcom Ventures. The inaugural fund will seek to identify and
![Humana and IBM Watson Health Collaborate to Simplify and Enhance the Member Experience for Humana Employer Group Customers: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=us)
Humana and IBM Watson Health Collaborate to Simplify and Enhance the Member Experience for Humana Employer Group Customers
Humana Inc. (NYSE: HUM) and IBM (NYSE: IBM) Watson Health today announced a collaboration leveraging IBM’s conversational artificial intelligence (AI) solution – to help provide a better member
![Humana Begins Coverage of Hospice Services as Part of Medicare Demonstration: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=us)
Humana Begins Coverage of Hospice Services as Part of Medicare Demonstration
Humana Inc. (NYSE: HUM) has begun evaluating a new way of offering hospice services to members of select Medicare Advantage plans in an attempt to provide greater continuity of care, additional
![Waters Redefines Laboratory Science with New ACQUITY PREMIER Liquid Chromatography Solution](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Waters Redefines Laboratory Science with New ACQUITY PREMIER Liquid Chromatography Solution
Waters Corporation (NYSE:WAT) today introduced the Waters™ ACQUITY™ PREMIER Solution, the next generation in liquid chromatographs featuring Waters’ breakthrough MaxPeak™ High Performance Surface
![Illumina to Webcast Upcoming Investor Conference Presentations](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Annual Global
![Impel NeuroPharma Partners With Veeva Systems to Build Integrated, Digital-First Commercial Foundation](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Impel NeuroPharma Partners With Veeva Systems to Build Integrated, Digital-First Commercial Foundation
Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of innovative medicines for central nervous system (CNS) diseases
![Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting
Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.
10th Annual SVB Leerink Global Healthcare Conference
Wednesday, Feb. 24 at 7:40 a.m
![Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle
Feb. 8, 2021 -- Illumina, Inc. (NASDAQ: ILMN) has selected nine new genomics companies to join the second global funding cycle of Illumina Accelerator in the U.S. and UK. The global company
![Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Patent and Trademark Office (USPTO) recently issued a U.S. Patent Term Extension (PTE) certificate for IBRANCE® (palbociclib). The certificate
![6 der 7 weltweit führenden Auftragsforschungsunternehmen kooperieren mit Veeva zur schnelleren Durchführung klinischer Studien für Sponsoren](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
6 der 7 weltweit führenden Auftragsforschungsunternehmen kooperieren mit Veeva zur schnelleren Durchführung klinischer Studien für Sponsoren
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass sechs der sieben weltweit führenden Auftragsforschungsunternehmen dem Veeva Vault CDMS-Partnerprogramm beigetreten sind. Die Beschleunigung der
![6 of the Top 7 Global CROs Partner With Veeva to Run Faster Clinical Trials for Sponsors](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
6 of the Top 7 Global CROs Partner With Veeva to Run Faster Clinical Trials for Sponsors
Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life
![6 of the Top 7 Global CROs Partner with Veeva to Run Faster Clinical Trials for Sponsors](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
6 of the Top 7 Global CROs Partner with Veeva to Run Faster Clinical Trials for Sponsors
Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life
![Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium
February 4, 2021 -- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Society of Medical Oncology (BSMO) which is running a new national pilot to evaluate the use of
![Epredia setzt Veeva MedTech-Lösungen zur Vereinheitlichung der Änderungskontrolle in den Bereichen Qualität und Regulierung ein](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Epredia setzt Veeva MedTech-Lösungen zur Vereinheitlichung der Änderungskontrolle in den Bereichen Qualität und Regulierung ein
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Epredia, ein weltweit führender Anbieter im Bereich der Präzisionsdiagnostik für Krebs und Gewebe, die Anwendungen Veeva Vault Quality und Veeva
![Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening
![Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory
Veeva Systems (NYSE: VEEV) today announced that Epredia, a global leader in precision cancer and tissue diagnostics, is adopting Veeva Vault Quality and Veeva Vault RIM applications to automate
![Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory
Veeva Systems (NYSE: VEEV) today announced that Epredia, a global leader in precision cancer and tissue diagnostics, is adopting Veeva Vault Quality and Veeva Vault RIM applications to automate
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 3, 2021.
Fourth
![Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Dexcom und Nick Jonas enthüllen den ersten Super Bowl-Werbespot und fordern eine bessere Versorgung von Menschen mit Diabetes
DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter von kontinuierlicher Blutzuckermessung für Menschen mit Diabetes, hat heute seinen allerersten Super-Bowl-Werbespot mit dem